- Kyowa Kirin International: New Real World Evidence Underlines Benefits of POTELIGEO®▼ (mogamulizumab) Treatment for Cutaneous T-cell Lymphoma (CTCL) Patients
- Kyowa Kirin and Amgen Present Positive Late-Breaking Data from Phase 2 Study of KHK4083/AMG 451 in Adult Patients with Moderate-to-Severe Atopic Dermatitis at EADV Congress
- Long-Term CRYSVITA® ▼ (burosumab) Treatment Reduces the Burden of Disease in Adults With X-Linked Hypophosphataemia (XLH), a Rare Genetic Metabolic Bone Disease
- Kyowa Kirin to Present Atopic Dermatitis Clinical Data from KHK4083/AMG 451 Phase 2 Study at The European Academy of Dermatology and Venereology 30th Congress
Kyowa Kirin Co Ltd (KY4:FRA) closed at 28.60, -13.33% below its 52-week high of 33.00, set on Sep 24, 2021.
20.80Dec 18 202033.00Sep 24 2021
Markit short selling activity
|Market cap||1.97tn JPY|
|EPS (TTM)||82.42 |
|Annual div (ADY)||0.3425 |
|Annual div yield (ADY)||1.25%|
|Div ex-date||Jun 29 2021|
|Div pay-date||Sep 01 2021|
|Next div ex-date||Dec 29 2021|
|Next div pay-date||--|
Data delayed at least 15 minutes, as of Oct 26 2021 15:01 BST.